Genome writing demand Replay’s core focus on high payload genome writing and its hub-and-spoke model indicate strong cross-sell potential to gene therapy product companies leveraging their synHSV platform and genome writing tech. Target therapeutic developers seeking scalable delivery of large DNA constructs could be receptive to expanded platform access and collaboration.

Platform expansion With multiple disruptive platforms including a high payload HSV vector and a hypoimmunogenic system, there are opportunities to offer bundled services or licensing to biotech firms pursuing advanced gene therapies, enabling joint development efforts across multiple indication areas such as skin, eye, brain, and muscle.

Enzyme writing offering Replay’s enzyme writing product line, powered by evolutionary inference and genome writing tech, opens up a sales path to biotech and pharma customers focused on enzyme optimization, potentially appealing to companies in industrial biotech, biocatalysis, and therapeutic manufacturing seeking improved enzyme performance.

Strategic partnerships The hub-and-spoke model creates clear collaboration avenues with product companies that can adopt Replay’s technology platforms, suggesting a channel partner strategy and co-development deals as a primary growth lever to scale therapy programs and expand platform reach.

Financial readiness With funding of around 55 million and revenue in the lower single-digit millions, there is appetite for strategic partnerships, milestone-based collaborations, and grant-supported programs. This highlights opportunities for tiered engagement, pilot projects, and proof-of-concept engagements to de-risk broader platform adoption.